ValuEngine downgraded shares of The Vitamin Shoppe (NYSE:VSI) from a buy rating to a hold rating in a research note published on Wednesday morning.
A number of other analysts also recently issued reports on VSI. Morgan Stanley reduced their price objective on The Vitamin Shoppe from $4.00 to $3.75 and set an equal weight rating on the stock in a research note on Wednesday, February 28th. Zacks Investment Research downgraded The Vitamin Shoppe from a hold rating to a sell rating in a research note on Friday, March 2nd. Three analysts have rated the stock with a sell rating and five have issued a hold rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $4.95.
Get The Vitamin Shoppe alerts:
NYSE:VSI opened at $5.00 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.44 and a current ratio of 1.88. The Vitamin Shoppe has a 1 year low of $2.95 and a 1 year high of $12.25. The company has a market capitalization of $121.16 million, a price-to-earnings ratio of 12.82 and a beta of 0.48.
The Vitamin Shoppe (NYSE:VSI) last released its quarterly earnings data on Wednesday, May 9th. The specialty retailer reported $0.10 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.10. The Vitamin Shoppe had a positive return on equity of 1.28% and a negative net margin of 22.80%. The business had revenue of $295.96 million for the quarter, compared to the consensus estimate of $293.44 million. equities analysts expect that The Vitamin Shoppe will post -0.19 earnings per share for the current fiscal year.
In related news, major shareholder Shah Capital Management bought 156,142 shares of the company’s stock in a transaction dated Monday, April 2nd. The stock was purchased at an average price of $4.03 per share, for a total transaction of $629,252.26. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.07% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new position in shares of The Vitamin Shoppe in the 1st quarter worth approximately $109,000. Lazard Asset Management LLC purchased a new position in shares of The Vitamin Shoppe in the 4th quarter worth approximately $115,000. Crossmark Global Holdings Inc. boosted its holdings in shares of The Vitamin Shoppe by 122.8% in the 4th quarter. Crossmark Global Holdings Inc. now owns 31,320 shares of the specialty retailer’s stock worth $138,000 after purchasing an additional 17,260 shares during the period. Macquarie Group Ltd. boosted its holdings in shares of The Vitamin Shoppe by 180.2% in the 4th quarter. Macquarie Group Ltd. now owns 52,681 shares of the specialty retailer’s stock worth $232,000 after purchasing an additional 33,881 shares during the period. Finally, Pinebridge Investments L.P. boosted its holdings in shares of The Vitamin Shoppe by 28.3% in the 4th quarter. Pinebridge Investments L.P. now owns 63,860 shares of the specialty retailer’s stock worth $281,000 after purchasing an additional 14,079 shares during the period. Hedge funds and other institutional investors own 97.71% of the company’s stock.
The Vitamin Shoppe Company Profile
Vitamin Shoppe, Inc, through its subsidiaries, operates as a omni-channel specialty retailer and contract manufacturer of nutritional products in the United States and internationally. It operates in two segments, Retail and Manufacturing. The company provides custom manufacturing and private labeling services for vitamin, mineral, and supplement products, as well as develops and markets own branded products.
To view ValuEngine’s full report, visit ValuEngine’s official website.